# Nuclide record alpha-9-oncology (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/alpha-9-oncology/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "alpha-9-oncology" ;
  schema:name "Alpha-9 Oncology"@en ;
  schema:description "Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours."@en ;
  schema:url <https://nuclide.cc/companies/alpha-9-oncology/>, <https://www.a9oncology.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.a9oncology.com/>, <https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/>, <https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/> ;
  schema:addressCountry "CA" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/pet/> .